Imperial College London
Alternate

Professor Trevor Hansel

Faculty of Medicine, National Heart & Lung Institute

Emeritus Professor of Respiratory Pharmacology
 
 
 
//

Contact

 

+44 (0)20 3312 5733t.hansel

 
 
//

Location

 

Imperial Clinical Respiratory ReMint WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Spadaro:2019:10.1186/s12950-018-0202-y,
author = {Spadaro, S and Park, M and Turrini, C and Tunstall, T and Thwaites, R and Mauri, T and Ragazzi, R and Ruggeri, P and Hansel, TT and Caramori, G and Volta, CA},
doi = {10.1186/s12950-018-0202-y},
journal = {Journal of Inflammation},
title = {Biomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine},
url = {http://dx.doi.org/10.1186/s12950-018-0202-y},
volume = {16},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Acute lung injury (ALI) affects over 10% of patients hospitalised in critical care, with acute respiratory distress syndrome (ARDS) being the most severe form of ALI and having a mortality rate in the region of 40%. There has been slow but incremental progress in identification of biomarkers that contribute to the pathophysiology of ARDS, have utility in diagnosis and monitoring, and that are potential therapeutic targets (Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, Thompson T, Ware LB, Matthay MA, Lancet Respir Med 2014, 2:611–-620). However, a major issue is that ARDS is such a heterogeneous, multi-factorial, end-stage condition that the strategies for “lumping and splitting” are critical (Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX, Am J Respir Crit Care Med 2016, 194:147–-155). Nevertheless, sequencing of the human genome, the availability of improved methods for analysis of transcription to mRNA (gene expression), and development of sensitive immunoassays has allowed the application of network biology to ARDS, with these biomarkers offering potential for personalised or precision medicine (Sweeney TE, Khatri P, Toward precision medicine Crit Care Med; 2017 45:934-939).Biomarker panels have potential applications in molecular phenotyping for identifying patients at risk of developing ARDS, diagnosis of ARDS, risk stratification and monitoring. Two subphenotypes of ARDS have been identified on the basis of blood biomarkers: hypo-inflammatory and hyper-inflammatory. The hyper-inflammatory subphenotype is associated with shock, metabolic acidosis and worst clinical outcomes. Biomarkers of particular interest have included interleukins (IL-6 and IL-8), interferon gamma (IFN-γ), surfactant proteins (SPD and SPB), von Willebrand factor antigen, angiopoietin 1/2 and plasminogen activator inhibitor-1 (PAI-1). In terms of gene expression (mRNA) in blood there have been found to be increases in neutrophil-re
AU  - Spadaro,S
AU  - Park,M
AU  - Turrini,C
AU  - Tunstall,T
AU  - Thwaites,R
AU  - Mauri,T
AU  - Ragazzi,R
AU  - Ruggeri,P
AU  - Hansel,TT
AU  - Caramori,G
AU  - Volta,CA
DO  - 10.1186/s12950-018-0202-y
PY  - 2019///
SN  - 1476-9255
TI  - Biomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine
T2  - Journal of Inflammation
UR  - http://dx.doi.org/10.1186/s12950-018-0202-y
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455790900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/66193
VL  - 16
ER  -
Download